Compare REZI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REZI | ACAD |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.3B |
| IPO Year | 2018 | 2000 |
| Metric | REZI | ACAD |
|---|---|---|
| Price | $19.63 | $29.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | ★ $39.67 | $30.55 |
| AVG Volume (30 Days) | ★ 2.6M | 1.7M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.68 | 0.20 |
| Revenue | ★ $7,472,000,000.00 | $726,437,000.00 |
| Revenue This Year | $6.81 | $18.80 |
| Revenue Next Year | $3.62 | $11.70 |
| P/E Ratio | ★ $29.38 | $148.65 |
| Revenue Growth | 10.52 | ★ 40.45 |
| 52 Week Low | $18.96 | $19.69 |
| 52 Week High | $45.29 | $30.96 |
| Indicator | REZI | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 30.95 | 57.27 |
| Support Level | N/A | $25.00 |
| Resistance Level | $33.09 | $30.96 |
| Average True Range (ATR) | 1.13 | 0.87 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 13.90 | 47.55 |
Resideo Technologies Inc is a manufacturer and developer of technology-driven products and components that provide critical comfort, energy management, and safety and security solutions. The company has two reportable segments; Products and Solutions segment offers temperature and humidity control, energy products and solutions, water and air solutions, smoke and carbon monoxide detection home safety products, security panels, sensors, peripherals, wire and cable, communications devices, video cameras, other home-related lifestyle convenience solutions; and ADI Global Distribution segment includes wholesale distributor of low-voltage security products including access control, fire detection, security, and video products. It derives majority of its revenue from the United States.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.